drugset / Trial / NCT04700618
A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old
Phase 4
Completed
330 enrolled
China National Biotec Group Company Limited
Shanghai Municipal Center for Disease Control and Prevention · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Objective: To evaluate the safety and immunogenicity of PPV23 vaccine revaccinated in 60-70 years old in Shanghai.
Timeline
- Start
- 2021-03-21
- Primary completion
- 2021-08-22
- Completion
- 2022-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pneumovax 23 | Vaccine | — | — |
Indications
No indication recorded.